Last reviewed · How we verify
Nexobrid (anacaulase)
Nexobrid works by breaking down the eschar, a dead layer of skin, to facilitate its removal.
At a glance
| Generic name | anacaulase |
|---|---|
| Sponsor | Mediwound, Ltd |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
| First approval | 2022 |
Mechanism of action
Imagine your skin as a layer of bricks. The eschar is like a thick layer of mortar that's holding those bricks together. Nexobrid helps to break down that mortar, making it easier to remove the dead skin and promote healing.
Approved indications
- Removal of escars from deep thermal burn
Common side effects
- Pruritus
- Pyrexia
Serious adverse events
- Anaphylaxis
- Hypersensitivity
- Urticaria
Key clinical trials
- A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) (PHASE3)
- Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nexobrid CI brief — competitive landscape report
- Nexobrid updates RSS · CI watch RSS
- Mediwound, Ltd portfolio CI